

Andrea Vergallo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2494555/andrea-vergallo-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

89
papers

2,059
citations

23
h-index

43
g-index

108
ext. papers

3,208
ext. citations

4.4
avg, IF

5.01
L-index

#	Paper	IF	Citations
89	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. <i>Brain</i> , 2018 , 141, 1917-1933	11.2	492
88	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019 , 15, 465-476	1.2	127
87	The β -Secretase BACE1 in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021 , 89, 745-756	7.9	107
86	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020 , 11, 456	8.4	87
85	Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019 , 15, 764-775	1.2	86
84	Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S47-S105	4.3	84
83	The Amyloid- β Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021 ,	15.1	63
82	Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research. <i>Journal of Prevention of Alzheimer's Disease</i> , 2019 , 6, 2-15	3.8	61
81	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018 , 130, 331-365	10.2	60
80	A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. <i>Journal of Clinical Psychopharmacology</i> , 2013 , 33, 691-4	1.7	59
79	The Alzheimer Precision Medicine Initiative. <i>Journal of Alzheimer's Disease</i> , 2019 , 68, 1-24	4.3	48
78	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1204-1215	1.2	40
77	Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019 , 15, 940-950	1.2	31
76	Migraine features in migraineurs with and without anxiety-depression symptoms: a hospital-based study. <i>Clinical Neurology and Neurosurgery</i> , 2015 , 132, 74-8	2	30
75	Association of cerebrospinal fluid β -synuclein with total and phospho-tau protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1623-1631	1.2	30
74	Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification. <i>Frontiers in Neuroendocrinology</i> , 2018 , 50, 31-51	8.9	29
73	Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 615-629	4.3	28

72	microRNA-Based Biomarkers in Alzheimer's Disease (AD). <i>Frontiers in Neuroscience</i> , 2020 , 14, 585432	5.1	28
71	Time for the systems-level integration of aging: Resilience enhancing strategies to prevent Alzheimer's disease. <i>Progress in Neurobiology</i> , 2019 , 181, 101662	10.9	26
70	Developing the ATX(N) classification for use across the Alzheimer disease continuum. <i>Nature Reviews Neurology</i> , 2021 , 17, 580-589	15	25
69	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019 , 83, 42-53	5.6	23
68	Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology. <i>Frontiers in Pharmacology</i> , 2019 , 10, 310	5.6	23
67	Affective theory of mind in patients with Parkinson's disease. <i>Psychiatry and Clinical Neurosciences</i> , 2013 , 67, 273-6	6.2	23
66	Triggers in allodynic and non-allodynic migraineurs. A clinic setting study. <i>Headache</i> , 2013 , 53, 152-160	4.2	23
65	How aware are migraineurs of their triggers?. <i>Headache</i> , 2013 , 53, 834-7	4.2	21
64	Early Detection of Mild Cognitive Impairment (MCI) in Primary Care. <i>Journal of Prevention of Alzheimer's Disease</i> , 2020 , 7, 165-170	3.8	21
63	The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. <i>Expert Review of Proteomics</i> , 2019 , 16, 593-600	4.2	20
62	Clinical features associated with ictal osmophobia in migraine. <i>Neurological Sciences</i> , 2015 , 36, 43-6	3.5	20
61	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 421-441	3.8	19
60	Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 15	9	17
59	Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. <i>Ageing Research Reviews</i> , 2021 , 69, 101346	12	17
58	Thyroid hormone levels in the cerebrospinal fluid correlate with disease severity in euthyroid patients with Alzheimer's disease. <i>Endocrine</i> , 2017 , 55, 981-984	4	15
57	Treatment of epilepsy in patients with Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 309-318	4.3	14
56	A single center study: A β 2/p-Tau CSF ratio to discriminate AD from FTD in clinical setting. <i>Neurological Sciences</i> , 2017 , 38, 1791-1797	3.5	13
55	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease?. <i>Dialogues in Clinical Neuroscience</i> , 2019 , 21, 177-191	5.7	13

54	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. <i>Neurology</i> , 2020 , 94, e30-e41	6.5	13
53	Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting. <i>Journal of Prevention of Alzheimer's Disease, The</i> , 2020 , 7, 171-178	3.8	12
52	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. <i>Neurobiology of Aging</i> , 2020 , 90, 43-59	5.6	12
51	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. <i>Neuropharmacology</i> , 2021 , 185, 108081	5.5	12
50	Oxidative Stress Assessment in Alzheimer's Disease: A Clinic Setting Study. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018 , 33, 35-41	2.5	11
49	In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020 , 93, 98-108	5.6	10
48	Occurrence of Takotsubo syndrome in a patient with Parkinson's disease after entacapone add-on. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1313-4	3.6	10
47	Bilateral thalamic infarct caused by spontaneous vertebral artery dissection in pre-eclampsia with HELLP syndrome: a previously unreported association. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012 , 21, 914.e9-10	2.8	10
46	Peri-ictal prolonged atrial fibrillation after generalized seizures: description of a case and etiopathological considerations. <i>Epilepsy and Behavior</i> , 2012 , 23, 377-8	3.2	10
45	Brain A β load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1274-1285	1.2	9
44	Blood-based diagnostics of Alzheimer's disease. <i>Expert Review of Molecular Diagnostics</i> , 2019 , 19, 613-621	3.8	8
43	Localized calcific hematoma of the scalp presenting as a nummular-like headache: a case report. <i>Headache</i> , 2014 , 54, 370-2	4.2	8
42	Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) Supported by Emerging Digital Technologies. <i>Journal of Prevention of Alzheimer's Disease, The</i> , 2020 , 7, 158-164	3.8	8
41	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 147	9	8
40	The Precuneus - A Witness for Excessive A β Gathering in Alzheimer's Disease Pathology. <i>Neurodegenerative Diseases</i> , 2018 , 18, 302-309	2.3	8
39	Association Between CSF Beta-Amyloid and Apathy in Early-Stage Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2019 , 32, 164-169	3.8	6
38	The role of synaptic biomarkers in the spectrum of neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2020 , 17, 543-559	4.2	6
37	State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	6

36	MiRNA-15b and miRNA-125b are associated with regional AβPET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. <i>Translational Psychiatry</i> , 2021 , 11, 78	8.6	6
35	Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 553-562	6	5
34	Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. <i>Journal of Personalized Medicine</i> , 2020 , 10,	3.6	5
33	Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force. <i>Journal of prevention of Alzheimer's disease, The</i> , 2021 , 8, 306-312	3.8	5
32	Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020 , 96, 22-32	5.6	4
31	Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force. <i>Journal of prevention of Alzheimer's disease, The</i> , 2021 , 8, 513-519	3.8	4
30	Plasma β-secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2021 , 17, 629-640	1.2	4
29	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020 , 88, 83-90	5.6	3
28	The Sars-Cov-2 Pandemic and the Brave New Digital World of Environmental Enrichment to Prevent Brain Aging and Cognitive Decline. <i>Journal of prevention of Alzheimer's disease, The</i> , 2020 , 7, 294-298	3.8	3
27	Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2021 , 18, 27-48	4.2	3
26	EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel. <i>Neurobiology of Aging</i> , 2021 , 103, 78-97	5.6	3
25	RE response to: "Entacapone, Parkinson's disease, "functional adrenergic denervation", and Takotsubo syndrome". <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 427	3.6	2
24	Toward Noninvasive Brain Stimulation 2.0 in Alzheimer's Disease.. <i>Ageing Research Reviews</i> , 2021 , 75, 101555	12	2
23	β-secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 130	9	2
22	Commentary: Development of the Blood-Based Alzheimer's Disease Liquid Biopsy. <i>Journal of prevention of Alzheimer's disease, The</i> , 2019 , 6, 182-184	3.8	1
21	Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis.. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 748198	5.3	1
20	Aptamer prediction of brain amyloid-β status in cognitively normal individuals at risk for Alzheimer's disease. <i>PLoS ONE</i> , 2021 , 16, e0243902	3.7	1
19	Association of plasma Aβ ₄₀ /Aβ ₄₂ ratio and brain Aβ accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021 , 107, 57-69	5.6	1

18	Evaluation of major national dementia policies and health-care system preparedness for early medical action and implementation.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	1
17	Sexual headache: two familiar orgasmic headache cases and review of the literature. <i>Acta Neurologica Belgica</i> , 2015 , 115, 757-8	1.5	0
16	Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's and other neurodegenerative diseases. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 949-967	4.3	0
15	Association of plasma YKL-40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041753	1.2	
14	Aging and sex impact plasma NFL and t-Tau trajectories in individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041792	1.2	
13	Sensitivity and specificity of EEG biomarkers of AD at the preclinical stage. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045832	1.2	
12	Cortical microstructural changes and amyloid beta burden in cognitively normal subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046014	1.2	
11	Sex differences in cortical microstructural changes in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046105	1.2	
10	Reply: Optimal use of cholinergic drugs in Alzheimer's disease. <i>Brain</i> , 2018 , 141, e69	11.2	
9	Paroxysmal exertion-induced dystonia secondary to Erdheim-Chester disease. <i>Clinical Neurology and Neurosurgery</i> , 2013 , 115, 1105-6	2	
8	LONGITUDINAL EFFECT OF BIOLOGICAL VARIABLES ON PLASMA NFL AND T-TAU CONCENTRATIONS ON SUBJECTIVE MEMORY COMPLAINERS (INSIGHT-PREAD-COHORT): A 3-YEAR FOLLOW-UP STUDY 2019 , 15, P213		
7	P4-072: INCREASED PLASMA BACE1 CONCENTRATIONS IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS: CORRELATION WITH PLASMA NFL 2018 , 14, P1461-P1462		
6	P2-237: ASSOCIATION OF CSF ALPHA-SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS 2018 , 14, P762-P762		
5	O3-09-02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOID-PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS 2018 , 14, P1036-P1037		
4	P4-186: INNOVATIVE BIOMARKER-GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEASE DEMENTIA 2018 , 14, P1510-P1511		
3	P2-246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKL-40 CONCENTRATIONS IN AMYLOID-PET POSITIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS 2018 , 14, P767-P768		
2	P2-249: CORRELATIONS AND ALTERED LONGITUDINAL DYNAMICS OF PLASMA BACE1 AND NFL CONCENTRATIONS IN INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS 2018 , 14, P768-P769		
1	P2-355: CORRELATION OF FUNCTIONAL MRI CONNECTOMES WITH PATHOPHYSIOLOGICAL ALZHEIMER'S PLASMA BIOMARKERS AND RISK FACTORS IN SUBJECTIVE MEMORY COMPLAINERS 2018 , 14, P824-P825		

